Eli Lilly and Company (LLY) 85.57 $LLY
Will Currency and Generics Hit Eli Lilly's Q2 Earnings? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 5:38PM CDT
Eli Lilly (LLY) will be facing headwinds in the form of generic competition and currency movement.
MDCO: 33.85 (+0.13), AMAG: 72.59 (-1.83), LLY: 85.57 (-2.30), NVS: 103.71 (-2.41)
Look for Shares of Eli Lilly to Potentially Rebound after Yesterday's 2.62% Sell Off
Comtex SmarTrend(R) - Tue Jul 21, 3:50PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $85.52 to a high of $87.69. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $86.58 on volume of 8.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 85.57 (-2.30)
Eli Lilly Set to Possibly Rebound After Yesterday's Selloff of 2.62%
Comtex SmarTrend(R) - Tue Jul 21, 3:49PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $85.52 to a high of $87.69. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $86.58 on volume of 8.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 85.57 (-2.30)
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
AGN: 317.00 (-0.75), JNJ: 100.34 (-0.03), ACHN: 9.26 (-0.10), PFE: 35.14 (-0.10), ABBV: 70.54 (-0.26), JUNO: 50.10 (-0.03), LLY: 85.57 (-2.30), SNY: 52.99 (-0.26)
Pharma Stock Outlook - July 2015 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Industry Outlook
AGN: 317.00 (-0.75), JNJ: 100.34 (-0.03), ACHN: 9.26 (-0.10), PFE: 35.14 (-0.10), ABBV: 70.54 (-0.26), JUNO: 50.10 (-0.03), LLY: 85.57 (-2.30), SNY: 52.99 (-0.26)
On Tap: Eli Lilly's Big Hopes in Alzheimer's Disease
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 21, 11:54AM CDT
Source: Eli Lilly Pharmaceutical Goliath Eli Lilly and Company is scheduled to update the world on its progress in slowing the ever-worsening effects of Alzheimer's disease at a key industry conference tomorrow. Innovating care in a...
LLY: 85.57 (-2.30)
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History
ESTMZ - Tue Jul 21, 11:24AM CDT
Welcome to the July 21st edition of This Week on Estimize. We are pleased to be joined by Joe McCann, former biotech analyst and founder of Slingshot Insights, a company that works to provide professional caliber investment tools to sophisticated...
BIIB: 409.50 (+0.57), SPY: 211.75 (-0.84), GILD: 117.78 (-0.42), ZGNX: 20.72 (+0.34), UTHR: 175.17 (-2.34), RTRX: 34.47 (-0.68), LLY: 85.57 (-2.30), CELG: 136.24 (+1.01), XOMA: 4.39 (-0.13)
Major Depressive Disorder Pipeline Review, H1 2015 - 37 Companies & 32 Drug Profiles
M2 - Tue Jul 21, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6wpzn/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - Alkermes Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics plc - Edgemont Pharmaceuticals, LLC - Eli Lilly and Company - Euthymics Bioscience, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. Drug Profiles - (aripiprazole sertraline) - (samidorphan buprenorphine hydrochloride) - amitifadine - AN-788 - aripiprazole - AV-101 - AVP-786 - basimglurant - brexpiprazole - bupropion hydrochloride ER - cariprazine - CERC-301 - desvenlafaxine succinate SR - EDG-005 - edivoxetine - esketamine hydrochloride - INASTR-001 - ITI-007 - lurasidone hydrochloride - LY-03005 - LY-2940094 - MIN-117 - miR-135 - MSI-195 - NLF-NEU - NRX-1074 - NSI-189 - onabotulinumtoxin A - PH-10 - rapastinel - RP-5063 - SEP-363856 For more information visit http://www.researchandmarkets.com/research/m6...depressive
JNJ: 100.34 (-0.03), ITCI: 28.95 (-1.15), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), BMY: 68.87 (-1.10), ALKS: 68.51 (-1.64), CUR: 1.72 (-0.03)
Low Back Pain Therapeutics Pipeline Review 2015 - 17 Companies & 19 Drug Profiles
M2 - Tue Jul 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrggl2/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Collegium Pharmaceutical, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Ipsen S.A. - MEDRx Co., Ltd. - Merck & Co., Inc. - Mesoblast Limited - Nektar Therapeutics - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Pfizer Inc. - Stayble Therapeutics - Teikoku Pharma USA, Inc. Drug Profiles - (acetaminophen tramadol hydrochloride) - (diclofenac sodium eperisone) - (etodolac lidocaine) - (etoricoxib tizanidine) - (oxycodone hydrochloride naltrexone) ER - AB-001 - abobotulinumtoxin A - ASP-7962 - Atx09-002 - bupivacaine hydrochloride - cebranopadol - Drug for Chronic Low Back Pain - duloxetine hydrochloride DR - eperisone SR - flurbiprofen sodium - MPC-06ID - NKTR-181 - oxycodone hydrochloride ER - PF-06372865 For more information visit http://www.researchandmarkets.com/research/qr..._back_pain
PFE: 35.14 (-0.10), MRK: 58.67 (-0.33), COLL: 18.73 (-0.62), LLY: 85.57 (-2.30), PCRX: 62.89 (-0.55), NKTR: 12.60 (+0.15), PTIE: 1.71 (unch)
Malignant Mesothelioma Therapeutics Pipeline Report 2015 - 50 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lx3h4b/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - Amphera BV - Applied Research using OMIC Sciences, S.L. - arGEN-X BV - ArQule, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - CanBas Co., Ltd. - Concordia Healthcare Corp. - CritiTech, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Genelux Corporation - GlaxoSmithKline plc - Juno Therapeutics Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/lx3h4b/malignant
ADRO: 28.50 (+0.80), ARQL: 1.84 (+0.01), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), EGRX: 87.74 (-2.83), BMY: 68.87 (-1.10), MRK: 58.67 (-0.33), AVEO: 1.68 (+0.06), CALA: 9.15 (+1.32), JUNO: 50.10 (-0.03), FPRX: 24.89 (-0.29), CXRX: 80.55 (+1.70)
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 25.56 (-0.83), NBS: 2.25 (-0.09), CLSN: 2.45 (-0.02), JNJ: 100.34 (-0.03), ABBV: 70.54 (-0.26), EXEL: 6.05 (+0.17), ONCY: 0.66 (+0.02), CERU: 4.26 (-0.07), PFE: 35.14 (-0.10), IMGN: 18.65 (-0.23), AMGN: 163.70 (-0.64), LLY: 85.57 (-2.30), CLVS: 86.16 (+0.10), AZN: 67.64 (-0.21), MRK: 58.67 (-0.33), NVS: 103.71 (-2.41)
Diabetic Neuropathy Therapeutics Pipeline Review 2015 - 16 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phhqrf/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Araim Pharmaceuticals Inc. - Astellas Pharma Inc. - Cebix Incorporated - Eli Lilly and Company - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Spinifex Pharmaceuticals Pty Limited - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. Drug Profiles - Antimunocel - ARA-290 - ASP-8477 - BBI-21007 - Biologic for Diabetic Nephropathy - BNV-222 - capsaicin - CBX-129801 - Cyndacel-M - Drug for Peripheral Neuropathic Pain and Diabetic Peripheral Neuropathy - EMA-401 - ketoprofen - Lpathomab - Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - NRD-135SE1 - NSI-566 - OMS-721 - Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - PF-05089771 - ranirestat - Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - RTU-1096 - Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Small Molecules for Diabetic Neuropathy - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Synthetic Peptides for Central Nervous System Disorders and Diabetic Neuropathy - VBY-285 - VM-202 For more information visit http://www.researchandmarkets.com/research/phhqrf/diabetic
PFE: 35.14 (-0.10), LLY: 85.57 (-2.30), VBAY: (), ACOR: 34.46 (-0.83), LPTN: 0.27 (+0.01), OMER: 18.06 (-0.46), CUR: 1.72 (-0.03)
Watch for Shares of Eli Lilly (LLY) to Approach Support at $87.04
Comtex SmarTrend(R) - Tue Jul 21, 10:03AM CDT
Eli Lilly (NYSE:LLY) has opened bearishly below the pivot of $87.69 today and has reached the first level of support at $87.45. Analysts will be watching for a cross of the next downside pivot targets of $87.04 and $86.39.
LLY: 85.57 (-2.30)
PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board
Marketwired - Tue Jul 21, 8:05AM CDT
In the world of pharmaceuticals, the approval of a new drug is largely a matter of its relative performance rather than an absolute performance. That is, the therapy in question doesn't just have to work -- it has to work as good, or better, than the treatments currently approved for a particular disease.
LLY: 85.57 (-2.30), CELGZ: 2.19 (+0.01)
3 High-Dividend Pharmaceutical Stocks to Buy
at The Street - Tue Jul 21, 7:48AM CDT
With Eli Lilly & Co. experimenting with a new drug for Alzheimer's disease, we decided to check Quant Ratings for pharmaceutical stocks to buy.
JNJ: 100.34 (-0.03), PFE: 35.14 (-0.10), LLY: 85.57 (-2.30), NVS: 103.71 (-2.41)
Soft Tissue Sarcoma Therapeutics Pipeline Report 2015 - Review of 46 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vws7wm/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Altor BioScience Corporation - Amgen Inc. - Bayer AG - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - CASI Pharmaceuticals Inc. - Celgene Corporation - Cellectar Biosciences, Inc. - CytRx Corporation - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Exelixis, Inc. - Gem Pharmaceuticals, LLC - Immune Design Corp. - Karyopharm Therapeutics, Inc. - Loxo Oncology, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - MolMed S.p.A. - Morphotek, Inc. - Nanobiotix - Neotropix, Inc. - Novartis AG - Oncos Therapeutics Ltd. - Onxeo SA - Pfizer Inc. - Pharma Mar, S.A. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/vw...oft_tissue
LOXO: 17.44 (-0.35), CLRB: 3.55 (unch), IMDZ: 26.06 (-0.09), PFE: 35.14 (-0.10), AMGN: 163.70 (-0.64), LLY: 85.57 (-2.30), EPZM: 22.18 (+0.05), CASI: 1.66 (-0.02), MACK: 9.84 (-0.41), BLCM: 19.46 (-0.50), MRK: 58.67 (-0.33), CYTR: 3.04 (-0.76), MRTX: 31.46 (-1.51), NVS: 103.71 (-2.41), KPTI: 23.26 (-0.72), EXEL: 6.05 (+0.17), CELGZ: 2.19 (+0.01)
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Pipeline Review 2015 - Analysis of 35 Companies & 43 Drug Profiles
M2 - Tue Jul 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dp6kl/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Agios Pharmaceuticals, Inc. - Ariad Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca PLC - Bayer AG - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - CellAct Pharma GmbH - Concordia Healthcare Corp. - Cornerstone Pharmaceuticals, Inc. - Delcath Systems, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Komipharm International Co., Ltd. - Mebiopharm Co., Ltd. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - NuCana BioMed Limited - OncoTherapy Science, Inc. - Panacea Pharmaceuticals, Inc. - PCI Biotech AS - Pfizer Inc. - Provecs Medical GmbH - Sanofi - Senhwa Biosciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - AG-120 - ARN-5032 - ARQ-087 - BBI-503 - BGJ-398 - binimetinib - cabozantinib s-malate - CAP-7.1 - CC-90007 - CPI-613 - dasatinib - DKN-01 - elpamotide - evofosfamide - gemcitabine hydrochloride - Im-01 - KML-001 - MBPY-005 - melphalan - merestinib - MK-2206 - NUC-1031 - OCVC-01 - paclitaxel albumin bound - PAN-622 - pembrolizumab - ponatinib hydrochloride - porfimer sodium For more information visit http://www.researchandmarkets.com/research/6d...uct_cancer
PFE: 35.14 (-0.10), ARQL: 1.84 (+0.01), SPPI: 7.27 (-0.14), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), BMY: 68.87 (-1.10), MACK: 9.84 (-0.41), MRK: 58.67 (-0.33), AZN: 67.64 (-0.21), AGIO: 114.09 (-1.02), DCTH: 0.49 (-0.03), NVS: 103.71 (-2.41), ARRY: 6.73 (-0.06), CELGZ: 2.19 (+0.01), CXRX: 80.55 (+1.70), EXEL: 6.05 (+0.17)
Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H1 2015 - 23 Companies & 29 Drug Profiles
M2 - Tue Jul 21, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hs6grh/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ascendis Pharma A/S - AstraZeneca PLC - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Eli Lilly and Company - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - MarcoPolo Pharmaceuticals SA - Navigen Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited Drug Profiles - ACP-005 - aripiprazole - aripiprazole CR - BRDK-98958073 - cariprazine - CNV-1061436 - DP-VPA - Drug for Bipolar Disorder - Drug for Cancer and Neurodegenerative Disease - Endoxifen - ITI-007 - KP-303 - lurasidone hydrochloride - LY-2979165 - NP-202 - paliperidone palmitate - PGW-5 - quetiapine fumarate ER - ramelteon - risperidone - RP-5063 - SKL-PSY - Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - uridine triacetate - ziprasidone hydrochloride For more information visit http://www.researchandmarkets.com/research/hs...r_disorder
NBIX: 51.89 (-0.57), KMPH: 18.10 (+0.17), ASND: 21.00 (-0.43), ZGNX: 20.72 (+0.34), PFE: 35.14 (-0.10), AZN: 67.64 (-0.21), TEVA: 63.35 (-0.26), ITCI: 28.95 (-1.15), LLY: 85.57 (-2.30), OMER: 18.06 (-0.46)
Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges
M2 - Tue Jul 21, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kh4bs4/pharmaceutical) has announced the addition of the "Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges" report to their offering. This report tackles not only global pharmaceutical company interest in China but also home grown companies and their battle for position. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities. The Chinese Pharmaceutical market is currently the second greatest pharma market globally, after the US and in 2014 was worth $105 billion. It is forecast to increase dramatically to $200 billion by 2020 and increase its dominance as a leading player in Asia. This report describes the current therapeutics that are propelling the biopharmaceutical market in China. It examines the current economic climate and how China compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, diabetes and vaccines are elucidated and analysed. This study reveals market figures of the overall Chinese pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial and product review of key players in the biopharmaceutical industry in China. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. In summary, the Chinese biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment. Key Topics Covered: 1.0 Summary 2.0 Chronic Disease Prevalence Statistics 3.0 Business Environment 4.0 Chinese Pharmaceutical Market 5.0 Government and Regulation Environment 6.0 China - Second Largest Pharma Market 2014 7.0 Global Pharmaceutical Companies Interest in China 8.0 Chinese Pharmaceutical Companies 9.0 Drivers, Restraints, Challenges and Opportunity Analysis Companies Mentioned - Amoytop Biotech - Active Pharmaceutical Products - Beijing Continent Pharmaceuticals - FusoGen Pharmaceuticals - Shanghai Huaguan Biochip - SiBiono GeneTech - Abbott - AstraZeneca - Boehringer Ingelheim - Eli Lilly - GlaxoSmithKline - Johnson & Johnson Medical - Merck - Novartis - Pfizer - Roche For more information visit http://www.researchandmarkets.com/research/kh...maceutical
JNJ: 100.34 (-0.03), MRK: 58.67 (-0.33), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), NVS: 103.71 (-2.41)
Modality Solutions Names Judy Tempel Principal Consulting Engineer
PRWeb - Tue Jul 21, 2:35AM CDT
Modality Solutions, a company that delivers integrated cold chain management systems for highly regulated industries, is pleased to announce it has hired pharmaceutical veteran Judy Tempel as a principal consulting engineer. In her position as a Modality Solutions' Principal Consulting Engineer, Judy is working on cold chain technical support, storage, distribution, and accountability for clinical trials. She is currently responsible for clinical trial operations for vaccines for infectious diseases in challenging emerging markets.
LLY: 85.57 (-2.30)
Will Currency and Generics Hit Eli Lilly's Q2 Earnings? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 5:38PM CDT
Eli Lilly (LLY) will be facing headwinds in the form of generic competition and currency movement.
MDCO: 33.85 (+0.13), AMAG: 72.59 (-1.83), LLY: 85.57 (-2.30), NVS: 103.71 (-2.41)
Look for Shares of Eli Lilly to Potentially Rebound after Yesterday's 2.62% Sell Off
Comtex SmarTrend(R) - Tue Jul 21, 3:50PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $85.52 to a high of $87.69. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $86.58 on volume of 8.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 85.57 (-2.30)
Eli Lilly Set to Possibly Rebound After Yesterday's Selloff of 2.62%
Comtex SmarTrend(R) - Tue Jul 21, 3:49PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $85.52 to a high of $87.69. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $86.58 on volume of 8.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 85.57 (-2.30)
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
AGN: 317.00 (-0.75), JNJ: 100.34 (-0.03), ACHN: 9.26 (-0.10), PFE: 35.14 (-0.10), ABBV: 70.54 (-0.26), JUNO: 50.10 (-0.03), LLY: 85.57 (-2.30), SNY: 52.99 (-0.26)
Pharma Stock Outlook - July 2015 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Industry Outlook
AGN: 317.00 (-0.75), JNJ: 100.34 (-0.03), ACHN: 9.26 (-0.10), PFE: 35.14 (-0.10), ABBV: 70.54 (-0.26), JUNO: 50.10 (-0.03), LLY: 85.57 (-2.30), SNY: 52.99 (-0.26)
On Tap: Eli Lilly's Big Hopes in Alzheimer's Disease
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 21, 11:54AM CDT
Source: Eli Lilly Pharmaceutical Goliath Eli Lilly and Company is scheduled to update the world on its progress in slowing the ever-worsening effects of Alzheimer's disease at a key industry conference tomorrow. Innovating care in a...
LLY: 85.57 (-2.30)
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History
ESTMZ - Tue Jul 21, 11:24AM CDT
Welcome to the July 21st edition of This Week on Estimize. We are pleased to be joined by Joe McCann, former biotech analyst and founder of Slingshot Insights, a company that works to provide professional caliber investment tools to sophisticated...
BIIB: 409.50 (+0.57), SPY: 211.75 (-0.84), GILD: 117.78 (-0.42), ZGNX: 20.72 (+0.34), UTHR: 175.17 (-2.34), RTRX: 34.47 (-0.68), LLY: 85.57 (-2.30), CELG: 136.24 (+1.01), XOMA: 4.39 (-0.13)
Major Depressive Disorder Pipeline Review, H1 2015 - 37 Companies & 32 Drug Profiles
M2 - Tue Jul 21, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6wpzn/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - Alkermes Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics plc - Edgemont Pharmaceuticals, LLC - Eli Lilly and Company - Euthymics Bioscience, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. Drug Profiles - (aripiprazole sertraline) - (samidorphan buprenorphine hydrochloride) - amitifadine - AN-788 - aripiprazole - AV-101 - AVP-786 - basimglurant - brexpiprazole - bupropion hydrochloride ER - cariprazine - CERC-301 - desvenlafaxine succinate SR - EDG-005 - edivoxetine - esketamine hydrochloride - INASTR-001 - ITI-007 - lurasidone hydrochloride - LY-03005 - LY-2940094 - MIN-117 - miR-135 - MSI-195 - NLF-NEU - NRX-1074 - NSI-189 - onabotulinumtoxin A - PH-10 - rapastinel - RP-5063 - SEP-363856 For more information visit http://www.researchandmarkets.com/research/m6...depressive
JNJ: 100.34 (-0.03), ITCI: 28.95 (-1.15), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), BMY: 68.87 (-1.10), ALKS: 68.51 (-1.64), CUR: 1.72 (-0.03)
Low Back Pain Therapeutics Pipeline Review 2015 - 17 Companies & 19 Drug Profiles
M2 - Tue Jul 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrggl2/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Collegium Pharmaceutical, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Ipsen S.A. - MEDRx Co., Ltd. - Merck & Co., Inc. - Mesoblast Limited - Nektar Therapeutics - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Pfizer Inc. - Stayble Therapeutics - Teikoku Pharma USA, Inc. Drug Profiles - (acetaminophen tramadol hydrochloride) - (diclofenac sodium eperisone) - (etodolac lidocaine) - (etoricoxib tizanidine) - (oxycodone hydrochloride naltrexone) ER - AB-001 - abobotulinumtoxin A - ASP-7962 - Atx09-002 - bupivacaine hydrochloride - cebranopadol - Drug for Chronic Low Back Pain - duloxetine hydrochloride DR - eperisone SR - flurbiprofen sodium - MPC-06ID - NKTR-181 - oxycodone hydrochloride ER - PF-06372865 For more information visit http://www.researchandmarkets.com/research/qr..._back_pain
PFE: 35.14 (-0.10), MRK: 58.67 (-0.33), COLL: 18.73 (-0.62), LLY: 85.57 (-2.30), PCRX: 62.89 (-0.55), NKTR: 12.60 (+0.15), PTIE: 1.71 (unch)
Malignant Mesothelioma Therapeutics Pipeline Report 2015 - 50 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lx3h4b/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - Amphera BV - Applied Research using OMIC Sciences, S.L. - arGEN-X BV - ArQule, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - CanBas Co., Ltd. - Concordia Healthcare Corp. - CritiTech, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Genelux Corporation - GlaxoSmithKline plc - Juno Therapeutics Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/lx3h4b/malignant
ADRO: 28.50 (+0.80), ARQL: 1.84 (+0.01), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), EGRX: 87.74 (-2.83), BMY: 68.87 (-1.10), MRK: 58.67 (-0.33), AVEO: 1.68 (+0.06), CALA: 9.15 (+1.32), JUNO: 50.10 (-0.03), FPRX: 24.89 (-0.29), CXRX: 80.55 (+1.70)
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 25.56 (-0.83), NBS: 2.25 (-0.09), CLSN: 2.45 (-0.02), JNJ: 100.34 (-0.03), ABBV: 70.54 (-0.26), EXEL: 6.05 (+0.17), ONCY: 0.66 (+0.02), CERU: 4.26 (-0.07), PFE: 35.14 (-0.10), IMGN: 18.65 (-0.23), AMGN: 163.70 (-0.64), LLY: 85.57 (-2.30), CLVS: 86.16 (+0.10), AZN: 67.64 (-0.21), MRK: 58.67 (-0.33), NVS: 103.71 (-2.41)
Diabetic Neuropathy Therapeutics Pipeline Review 2015 - 16 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phhqrf/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Araim Pharmaceuticals Inc. - Astellas Pharma Inc. - Cebix Incorporated - Eli Lilly and Company - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Spinifex Pharmaceuticals Pty Limited - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. Drug Profiles - Antimunocel - ARA-290 - ASP-8477 - BBI-21007 - Biologic for Diabetic Nephropathy - BNV-222 - capsaicin - CBX-129801 - Cyndacel-M - Drug for Peripheral Neuropathic Pain and Diabetic Peripheral Neuropathy - EMA-401 - ketoprofen - Lpathomab - Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - NRD-135SE1 - NSI-566 - OMS-721 - Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - PF-05089771 - ranirestat - Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - RTU-1096 - Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Small Molecules for Diabetic Neuropathy - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Synthetic Peptides for Central Nervous System Disorders and Diabetic Neuropathy - VBY-285 - VM-202 For more information visit http://www.researchandmarkets.com/research/phhqrf/diabetic
PFE: 35.14 (-0.10), LLY: 85.57 (-2.30), VBAY: (), ACOR: 34.46 (-0.83), LPTN: 0.27 (+0.01), OMER: 18.06 (-0.46), CUR: 1.72 (-0.03)
Watch for Shares of Eli Lilly (LLY) to Approach Support at $87.04
Comtex SmarTrend(R) - Tue Jul 21, 10:03AM CDT
Eli Lilly (NYSE:LLY) has opened bearishly below the pivot of $87.69 today and has reached the first level of support at $87.45. Analysts will be watching for a cross of the next downside pivot targets of $87.04 and $86.39.
LLY: 85.57 (-2.30)
PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board
Marketwired - Tue Jul 21, 8:05AM CDT
In the world of pharmaceuticals, the approval of a new drug is largely a matter of its relative performance rather than an absolute performance. That is, the therapy in question doesn't just have to work -- it has to work as good, or better, than the treatments currently approved for a particular disease.
LLY: 85.57 (-2.30), CELGZ: 2.19 (+0.01)
3 High-Dividend Pharmaceutical Stocks to Buy
at The Street - Tue Jul 21, 7:48AM CDT
With Eli Lilly & Co. experimenting with a new drug for Alzheimer's disease, we decided to check Quant Ratings for pharmaceutical stocks to buy.
JNJ: 100.34 (-0.03), PFE: 35.14 (-0.10), LLY: 85.57 (-2.30), NVS: 103.71 (-2.41)
Soft Tissue Sarcoma Therapeutics Pipeline Report 2015 - Review of 46 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vws7wm/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Altor BioScience Corporation - Amgen Inc. - Bayer AG - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - CASI Pharmaceuticals Inc. - Celgene Corporation - Cellectar Biosciences, Inc. - CytRx Corporation - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Exelixis, Inc. - Gem Pharmaceuticals, LLC - Immune Design Corp. - Karyopharm Therapeutics, Inc. - Loxo Oncology, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - MolMed S.p.A. - Morphotek, Inc. - Nanobiotix - Neotropix, Inc. - Novartis AG - Oncos Therapeutics Ltd. - Onxeo SA - Pfizer Inc. - Pharma Mar, S.A. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/vw...oft_tissue
LOXO: 17.44 (-0.35), CLRB: 3.55 (unch), IMDZ: 26.06 (-0.09), PFE: 35.14 (-0.10), AMGN: 163.70 (-0.64), LLY: 85.57 (-2.30), EPZM: 22.18 (+0.05), CASI: 1.66 (-0.02), MACK: 9.84 (-0.41), BLCM: 19.46 (-0.50), MRK: 58.67 (-0.33), CYTR: 3.04 (-0.76), MRTX: 31.46 (-1.51), NVS: 103.71 (-2.41), KPTI: 23.26 (-0.72), EXEL: 6.05 (+0.17), CELGZ: 2.19 (+0.01)
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Pipeline Review 2015 - Analysis of 35 Companies & 43 Drug Profiles
M2 - Tue Jul 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dp6kl/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Agios Pharmaceuticals, Inc. - Ariad Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca PLC - Bayer AG - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - CellAct Pharma GmbH - Concordia Healthcare Corp. - Cornerstone Pharmaceuticals, Inc. - Delcath Systems, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Komipharm International Co., Ltd. - Mebiopharm Co., Ltd. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - NuCana BioMed Limited - OncoTherapy Science, Inc. - Panacea Pharmaceuticals, Inc. - PCI Biotech AS - Pfizer Inc. - Provecs Medical GmbH - Sanofi - Senhwa Biosciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - AG-120 - ARN-5032 - ARQ-087 - BBI-503 - BGJ-398 - binimetinib - cabozantinib s-malate - CAP-7.1 - CC-90007 - CPI-613 - dasatinib - DKN-01 - elpamotide - evofosfamide - gemcitabine hydrochloride - Im-01 - KML-001 - MBPY-005 - melphalan - merestinib - MK-2206 - NUC-1031 - OCVC-01 - paclitaxel albumin bound - PAN-622 - pembrolizumab - ponatinib hydrochloride - porfimer sodium For more information visit http://www.researchandmarkets.com/research/6d...uct_cancer
PFE: 35.14 (-0.10), ARQL: 1.84 (+0.01), SPPI: 7.27 (-0.14), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), BMY: 68.87 (-1.10), MACK: 9.84 (-0.41), MRK: 58.67 (-0.33), AZN: 67.64 (-0.21), AGIO: 114.09 (-1.02), DCTH: 0.49 (-0.03), NVS: 103.71 (-2.41), ARRY: 6.73 (-0.06), CELGZ: 2.19 (+0.01), CXRX: 80.55 (+1.70), EXEL: 6.05 (+0.17)
Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H1 2015 - 23 Companies & 29 Drug Profiles
M2 - Tue Jul 21, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hs6grh/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ascendis Pharma A/S - AstraZeneca PLC - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Eli Lilly and Company - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - MarcoPolo Pharmaceuticals SA - Navigen Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited Drug Profiles - ACP-005 - aripiprazole - aripiprazole CR - BRDK-98958073 - cariprazine - CNV-1061436 - DP-VPA - Drug for Bipolar Disorder - Drug for Cancer and Neurodegenerative Disease - Endoxifen - ITI-007 - KP-303 - lurasidone hydrochloride - LY-2979165 - NP-202 - paliperidone palmitate - PGW-5 - quetiapine fumarate ER - ramelteon - risperidone - RP-5063 - SKL-PSY - Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - uridine triacetate - ziprasidone hydrochloride For more information visit http://www.researchandmarkets.com/research/hs...r_disorder
NBIX: 51.89 (-0.57), KMPH: 18.10 (+0.17), ASND: 21.00 (-0.43), ZGNX: 20.72 (+0.34), PFE: 35.14 (-0.10), AZN: 67.64 (-0.21), TEVA: 63.35 (-0.26), ITCI: 28.95 (-1.15), LLY: 85.57 (-2.30), OMER: 18.06 (-0.46)
Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges
M2 - Tue Jul 21, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kh4bs4/pharmaceutical) has announced the addition of the "Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges" report to their offering. This report tackles not only global pharmaceutical company interest in China but also home grown companies and their battle for position. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities. The Chinese Pharmaceutical market is currently the second greatest pharma market globally, after the US and in 2014 was worth $105 billion. It is forecast to increase dramatically to $200 billion by 2020 and increase its dominance as a leading player in Asia. This report describes the current therapeutics that are propelling the biopharmaceutical market in China. It examines the current economic climate and how China compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, diabetes and vaccines are elucidated and analysed. This study reveals market figures of the overall Chinese pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial and product review of key players in the biopharmaceutical industry in China. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. In summary, the Chinese biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment. Key Topics Covered: 1.0 Summary 2.0 Chronic Disease Prevalence Statistics 3.0 Business Environment 4.0 Chinese Pharmaceutical Market 5.0 Government and Regulation Environment 6.0 China - Second Largest Pharma Market 2014 7.0 Global Pharmaceutical Companies Interest in China 8.0 Chinese Pharmaceutical Companies 9.0 Drivers, Restraints, Challenges and Opportunity Analysis Companies Mentioned - Amoytop Biotech - Active Pharmaceutical Products - Beijing Continent Pharmaceuticals - FusoGen Pharmaceuticals - Shanghai Huaguan Biochip - SiBiono GeneTech - Abbott - AstraZeneca - Boehringer Ingelheim - Eli Lilly - GlaxoSmithKline - Johnson & Johnson Medical - Merck - Novartis - Pfizer - Roche For more information visit http://www.researchandmarkets.com/research/kh...maceutical
JNJ: 100.34 (-0.03), MRK: 58.67 (-0.33), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), NVS: 103.71 (-2.41)
Modality Solutions Names Judy Tempel Principal Consulting Engineer
PRWeb - Tue Jul 21, 2:35AM CDT
Modality Solutions, a company that delivers integrated cold chain management systems for highly regulated industries, is pleased to announce it has hired pharmaceutical veteran Judy Tempel as a principal consulting engineer. In her position as a Modality Solutions' Principal Consulting Engineer, Judy is working on cold chain technical support, storage, distribution, and accountability for clinical trials. She is currently responsible for clinical trial operations for vaccines for infectious diseases in challenging emerging markets.
LLY: 85.57 (-2.30)
